Skip to main content
Top
Published in: Osteoporosis International 10/2008

01-10-2008 | Review

Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines

Authors: M. Duyvendak, M. Naunton, E. N. van Roon, G. A. W. Bruyn, J. R. B. J. Brouwers

Published in: Osteoporosis International | Issue 10/2008

Login to get access

Abstract

Summary

Corticosteroid-induced osteoporosis (CIOP) is currently undertreated. Systematic review of the literature revealed that the percentage of patients treated adequately is dependent on study quality. Therefore, it remains unknown whether adherence to the guidelines is really so poor. Five major quality criteria provide the standard for future studies on this scope.

Introduction

It has recently been stated that the degree of prophylaxis of corticosteroid-induced osteoporosis (CIOP) is low and effort should be put into determining reasons for non-prescribing of preventive agents. The aim of this study was to identify: how many studies adequately audit the prevalent guideline; the longitudinal trends in prevention of CIOP; which patient groups appear to be most undertreated; and which intervention strategies are effective.

Methods

We performed a comprehensive search of MEDLINE and systematically recorded the outcomes and quality of published studies, using five major criteria.

Results

Twenty-four studies were included in the analysis. The quality of the included studies was poor (31%) or moderate (37%). There was a longitudinal increase in quality of the studies and percentage of prevention. Multivariable linear regression showed that the quality of the study was the only independent predictor of the prevention rate reported in the study.

Conclusions

The results show undertreatment of CIOP might be due to insufficient quality of the studies rather than poor practice or failure to recognise the right patients. Future interventions should comply with five major quality criteria, and a multifaceted approach is required in order to make an impact on the underprescribing of CIOP prophylaxis.
Literature
1.
go back to reference Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study. BMJ 313:344–346PubMed Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996) Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross-sectional study. BMJ 313:344–346PubMed
2.
go back to reference Staa van TP, Leufkens HGM, Abenhaim L, Begaud B, Zhang B, Cooper C (2000) Use of oral corticosteroids in the United Kingdom. QJM 93:105–111CrossRef Staa van TP, Leufkens HGM, Abenhaim L, Begaud B, Zhang B, Cooper C (2000) Use of oral corticosteroids in the United Kingdom. QJM 93:105–111CrossRef
3.
go back to reference Staa van TP, Leufkens HGM, Abenhaim L, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000CrossRef Staa van TP, Leufkens HGM, Abenhaim L, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000CrossRef
4.
go back to reference Gennari C (1994) Glucocorticoid induced osteoporosis. Clin Endocrinol (Oxf) 41:273–274CrossRef Gennari C (1994) Glucocorticoid induced osteoporosis. Clin Endocrinol (Oxf) 41:273–274CrossRef
5.
go back to reference Rackoff PJ, Rosen CJ (1998) Pathogenesis and treatment of glucocorticoid-induced osteoporosis. Drugs Aging 12:477–484PubMedCrossRef Rackoff PJ, Rosen CJ (1998) Pathogenesis and treatment of glucocorticoid-induced osteoporosis. Drugs Aging 12:477–484PubMedCrossRef
6.
go back to reference Yood RA (2006) Prevention of glucocorticoid-induced osteoporosis: why are we doing so poorly? J Rheumatol 33:1461–1463PubMed Yood RA (2006) Prevention of glucocorticoid-induced osteoporosis: why are we doing so poorly? J Rheumatol 33:1461–1463PubMed
7.
go back to reference Bell R, Carr A, Thompson P (1997) Managing corticosteroid induced osteoporosis in medical outpatients. J R Coll Physicians Lond 31:158–161PubMed Bell R, Carr A, Thompson P (1997) Managing corticosteroid induced osteoporosis in medical outpatients. J R Coll Physicians Lond 31:158–161PubMed
8.
go back to reference Buckley LM, Marquez M, Feezor R, Ruffin DM, Benson LL (1999) Prevention of corticosteroid-induced osteoporosis: results of a patient survey. Arthritis Rheum 42:1736–1739PubMedCrossRef Buckley LM, Marquez M, Feezor R, Ruffin DM, Benson LL (1999) Prevention of corticosteroid-induced osteoporosis: results of a patient survey. Arthritis Rheum 42:1736–1739PubMedCrossRef
9.
go back to reference Chattopadhyay I, Showkathali AR, Jain AK (2002) Osteoporosis prophylaxis during corticosteroid treatment. Postgrad Med J 78:572PubMedCrossRef Chattopadhyay I, Showkathali AR, Jain AK (2002) Osteoporosis prophylaxis during corticosteroid treatment. Postgrad Med J 78:572PubMedCrossRef
10.
go back to reference Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, Spettell CM, Weissman NW, Wilke S, Saag KG (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52:2485–2494PubMedCrossRef Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, Spettell CM, Weissman NW, Wilke S, Saag KG (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 52:2485–2494PubMedCrossRef
11.
go back to reference Dolan AL, Koshy E, Waker M, Goble CM (2004) Access to bone densitometry increases general practitioners’ prescribing for osteoporosis in steroid treated patients. Ann Rheum Dis 63:183–186PubMedCrossRef Dolan AL, Koshy E, Waker M, Goble CM (2004) Access to bone densitometry increases general practitioners’ prescribing for osteoporosis in steroid treated patients. Ann Rheum Dis 63:183–186PubMedCrossRef
12.
go back to reference Elliott ME, Farrah RM, Binkley NC, Carnes ML, Gudmundsson A (2000) Management of glucocorticoid-induced osteoporosis in male veterans. Ann Pharmacother 34:1380–1384PubMed Elliott ME, Farrah RM, Binkley NC, Carnes ML, Gudmundsson A (2000) Management of glucocorticoid-induced osteoporosis in male veterans. Ann Pharmacother 34:1380–1384PubMed
13.
go back to reference Erb N, Duncan RC, Raza K, Rowe IF, Kitas GD, Situnayake RD (2002) A regional audit of the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases in the West Midlands. Rheumatology (Oxford) 41:1021–1024CrossRef Erb N, Duncan RC, Raza K, Rowe IF, Kitas GD, Situnayake RD (2002) A regional audit of the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases in the West Midlands. Rheumatology (Oxford) 41:1021–1024CrossRef
14.
go back to reference Ettinger B, Chidambaran P, Pressman A (2001) Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 7:597–605PubMed Ettinger B, Chidambaran P, Pressman A (2001) Prevalence and determinants of osteoporosis drug prescription among patients with high exposure to glucocorticoid drugs. Am J Manag Care 7:597–605PubMed
15.
go back to reference Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005 Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005
16.
go back to reference Hart SR, Green B (2002) Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgrad Med J 78:242–243PubMedCrossRef Hart SR, Green B (2002) Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe. Postgrad Med J 78:242–243PubMedCrossRef
17.
go back to reference Hougardy DM, Peterson GM, Bleasel MD, Randall CT (2000) Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 25:227–234PubMedCrossRef Hougardy DM, Peterson GM, Bleasel MD, Randall CT (2000) Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 25:227–234PubMedCrossRef
18.
go back to reference Lewis SJ, Smith PE (2001) Osteoporosis prevention in myasthenia gravis: a reminder. Acta Neurol Scand 103:320–322PubMedCrossRef Lewis SJ, Smith PE (2001) Osteoporosis prevention in myasthenia gravis: a reminder. Acta Neurol Scand 103:320–322PubMedCrossRef
19.
go back to reference Lozsadi DA, Peters G, Sadik HY, Kellett MW, Fox SH, Smith DF (2006) Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg 108:157–162PubMedCrossRef Lozsadi DA, Peters G, Sadik HY, Kellett MW, Fox SH, Smith DF (2006) Prevention of osteoporosis in glucocorticoid-treated neurology patients. Clin Neurol Neurosurg 108:157–162PubMedCrossRef
20.
go back to reference Mudano A, Allison J, Hill J, Rothermel T, Saag K (2001) Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 28:1298–1305PubMed Mudano A, Allison J, Hill J, Rothermel T, Saag K (2001) Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort. J Rheumatol 28:1298–1305PubMed
21.
go back to reference Naganathan V, Sambrook P (2001) Osteoporosis and fracture risk prevention in long-term glucocorticoid therapy, authors reply. Arch Intern Med 161:1781 Naganathan V, Sambrook P (2001) Osteoporosis and fracture risk prevention in long-term glucocorticoid therapy, authors reply. Arch Intern Med 161:1781
22.
go back to reference Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD (2004) Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 31:550–556PubMed Naunton M, Peterson GM, Jones G, Griffin GM, Bleasel MD (2004) Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis. J Rheumatol 31:550–556PubMed
23.
go back to reference Osiri M, Saag KG, Ford AM, Moreland LW (2000) Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis. J Clin Rheumatol 6:117–122CrossRefPubMed Osiri M, Saag KG, Ford AM, Moreland LW (2000) Practice pattern variation among internal medicine specialists in the prevention of glucocorticoid-induced osteoporosis. J Clin Rheumatol 6:117–122CrossRefPubMed
24.
go back to reference Rothberg AD, Matshidze PK (2000) Monitoring and management of bone status in patients on chronic glucocorticoid treatment-the Medscheme experience. S Afr Med J 90:1125–1129PubMed Rothberg AD, Matshidze PK (2000) Monitoring and management of bone status in patients on chronic glucocorticoid treatment-the Medscheme experience. S Afr Med J 90:1125–1129PubMed
25.
go back to reference Saag KG, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL (2006) Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 33:1651–1657PubMed Saag KG, Gehlbach SH, Curtis JR, Youket TE, Worley K, Lange JL (2006) Trends in prevention of glucocorticoid-induced osteoporosis. J Rheumatol 33:1651–1657PubMed
26.
go back to reference Smith GD, Stevens DL, Fuller GN (2001) Myasthenia gravis, corticosteroids and osteoporosis prophylaxis. J Neurol 248:151PubMedCrossRef Smith GD, Stevens DL, Fuller GN (2001) Myasthenia gravis, corticosteroids and osteoporosis prophylaxis. J Neurol 248:151PubMedCrossRef
27.
go back to reference Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 46:3136–3142PubMedCrossRef Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J (2002) Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 46:3136–3142PubMedCrossRef
28.
go back to reference Solomon DH, Katz JN, Cabral D, Patrick AR, Bukowski JF, Coblyn JS (2006) Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement. Arthritis Rheum 55:873–877PubMedCrossRef Solomon DH, Katz JN, Cabral D, Patrick AR, Bukowski JF, Coblyn JS (2006) Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement. Arthritis Rheum 55:873–877PubMedCrossRef
29.
go back to reference Walker-Bone K, Wood A, Hull R, Ledingham JM, McCrae FC, Shaban R, Thomas A, Mackay K (2004) The prevention and treatment of glucocorticoid-induced osteoporosis in clinical practice. Clin Med 4:431–436PubMed Walker-Bone K, Wood A, Hull R, Ledingham JM, McCrae FC, Shaban R, Thomas A, Mackay K (2004) The prevention and treatment of glucocorticoid-induced osteoporosis in clinical practice. Clin Med 4:431–436PubMed
30.
go back to reference Aagaard EM, Lin P, Modin GW, Lane NE (1999) Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med 107:456–460PubMedCrossRef Aagaard EM, Lin P, Modin GW, Lane NE (1999) Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med 107:456–460PubMedCrossRef
31.
go back to reference Chantler IW, Davie MW, Evans SF, Rees JS (2003) Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 62:350–352PubMedCrossRef Chantler IW, Davie MW, Evans SF, Rees JS (2003) Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. Ann Rheum Dis 62:350–352PubMedCrossRef
32.
go back to reference Cruse LM, Valeriano J, Vasey FB, Carter JD (2006) Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 12:221–225PubMedCrossRef Cruse LM, Valeriano J, Vasey FB, Carter JD (2006) Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 12:221–225PubMedCrossRef
33.
go back to reference Gudbjornsson B, Juliusson UI, Gudjonsson FV (2002) Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61:32–36PubMedCrossRef Gudbjornsson B, Juliusson UI, Gudjonsson FV (2002) Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61:32–36PubMedCrossRef
34.
go back to reference Hodgkins PR, Hull RG, Vakalis A, Cole A, Hallet C, Evans AR, Jeffrey MN (1997) Long-term oral corticosteroids and osteoporosis prevention in an ophthalmology clinic. Eye 11(Pt 1):126–127PubMed Hodgkins PR, Hull RG, Vakalis A, Cole A, Hallet C, Evans AR, Jeffrey MN (1997) Long-term oral corticosteroids and osteoporosis prevention in an ophthalmology clinic. Eye 11(Pt 1):126–127PubMed
35.
go back to reference Karcic E, Karcic AA (2001) Osteoporosis and fracture risk prevention in long-term glucocorticoid therapy. Arch Intern Med 161:1780–1781PubMedCrossRef Karcic E, Karcic AA (2001) Osteoporosis and fracture risk prevention in long-term glucocorticoid therapy. Arch Intern Med 161:1780–1781PubMedCrossRef
36.
go back to reference Liu RH, Albrecht J, Werth VP (2006) Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol 142:37–41PubMedCrossRef Liu RH, Albrecht J, Werth VP (2006) Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy. Arch Dermatol 142:37–41PubMedCrossRef
37.
go back to reference McDonough RP, Doucette WR, Kumbera P, Klepser DG (2005) An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis. Value Health 8:24–31PubMedCrossRef McDonough RP, Doucette WR, Kumbera P, Klepser DG (2005) An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis. Value Health 8:24–31PubMedCrossRef
38.
go back to reference Miah S, Taylor R, McKellar G, Hunter J (2003) Corticosteroid-induced osteoporosis. Rheumatology (Oxford) 42:1118–1120CrossRef Miah S, Taylor R, McKellar G, Hunter J (2003) Corticosteroid-induced osteoporosis. Rheumatology (Oxford) 42:1118–1120CrossRef
39.
go back to reference Olesen C, Sorensen HT, Steffensen FH, Nielsen GL, Olsen J (1996) Danish data confirm low prevalence of HRT among women prescribed oral corticosteroids. BMJ 313:1264PubMed Olesen C, Sorensen HT, Steffensen FH, Nielsen GL, Olsen J (1996) Danish data confirm low prevalence of HRT among women prescribed oral corticosteroids. BMJ 313:1264PubMed
40.
go back to reference Peat ID, Healy S, Reid DM, Ralston SH (1995) Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis 54:66–68PubMedCrossRef Peat ID, Healy S, Reid DM, Ralston SH (1995) Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis 54:66–68PubMedCrossRef
41.
go back to reference Smith MD, Cheah SP, Taylor K, Ahern MJ (2001) Prevention of corticosteroid induced osteoporosis in inpatients recently discharged from a tertiary teaching hospital. J Rheumatol 28:566–570PubMed Smith MD, Cheah SP, Taylor K, Ahern MJ (2001) Prevention of corticosteroid induced osteoporosis in inpatients recently discharged from a tertiary teaching hospital. J Rheumatol 28:566–570PubMed
42.
go back to reference Solomon DH, Katz JN, La Tourette AM, Coblyn JS (2004) Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 51:383–387PubMedCrossRef Solomon DH, Katz JN, La Tourette AM, Coblyn JS (2004) Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum 51:383–387PubMedCrossRef
43.
go back to reference Yood RA, Harrold LR, Fish L, Cernieux J, Emani S, Conboy E, Gurwitz JH (2001) Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med 161:1322–1327PubMedCrossRef Yood RA, Harrold LR, Fish L, Cernieux J, Emani S, Conboy E, Gurwitz JH (2001) Prevention of glucocorticoid-induced osteoporosis: experience in a managed care setting. Arch Intern Med 161:1322–1327PubMedCrossRef
44.
go back to reference Eastell R (1995) Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med 237:439–447PubMed Eastell R (1995) Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med 237:439–447PubMed
45.
go back to reference American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (1996) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 39:1791–1801CrossRef American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (1996) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 39:1791–1801CrossRef
46.
go back to reference American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44:1496–1503CrossRef American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis (2001) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44:1496–1503CrossRef
47.
go back to reference Sambrook PN, Diamond T, Ferris L, Fiatarone-Singh M, Flicker L, MacLennan A, Nowson C, O’Neill S, Greville H (2001) Corticosteroid induced osteoporosis. Guidelines for treatment. Aust Fam Physician 30:793–796PubMed Sambrook PN, Diamond T, Ferris L, Fiatarone-Singh M, Flicker L, MacLennan A, Nowson C, O’Neill S, Greville H (2001) Corticosteroid induced osteoporosis. Guidelines for treatment. Aust Fam Physician 30:793–796PubMed
48.
go back to reference Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8–19PubMedCrossRef Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY, Rozenberg S, Boutsen Y (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17:8–19PubMedCrossRef
49.
go back to reference de Nijs RNJ, Bijlsma JWJ, Geusens P, Laan RFJM, Lems WF, Struijs A, van Staa TP (2002) Round table meeting: Prevention and treatment of glucocorticosteroid induced osteoporosis. Ned Tijdschr Rheumatol 1:12–17 de Nijs RNJ, Bijlsma JWJ, Geusens P, Laan RFJM, Lems WF, Struijs A, van Staa TP (2002) Round table meeting: Prevention and treatment of glucocorticosteroid induced osteoporosis. Ned Tijdschr Rheumatol 1:12–17
50.
go back to reference Pols HAPP, Wittenberg J (2002) CBO-guideline osteoporosis (second revision). Ned Tijdschr Geneeskd 146:1359–1363PubMed Pols HAPP, Wittenberg J (2002) CBO-guideline osteoporosis (second revision). Ned Tijdschr Geneeskd 146:1359–1363PubMed
51.
go back to reference Diamond T, McGuigan L, Barbagallo S, Bryant C (1995) Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 98:459–463PubMedCrossRef Diamond T, McGuigan L, Barbagallo S, Bryant C (1995) Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 98:459–463PubMedCrossRef
52.
go back to reference Struys A, Snelder AA, Mulder H (1995) Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235–242PubMedCrossRef Struys A, Snelder AA, Mulder H (1995) Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235–242PubMedCrossRef
53.
go back to reference Mulder H, Struys A (1994) Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 33:348–350PubMedCrossRef Mulder H, Struys A (1994) Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 33:348–350PubMedCrossRef
54.
go back to reference Skingle SJ, Crisp AJ (1994) Increased bone density in patients on steroids with etidronate. Lancet 344:543–544PubMedCrossRef Skingle SJ, Crisp AJ (1994) Increased bone density in patients on steroids with etidronate. Lancet 344:543–544PubMedCrossRef
55.
go back to reference Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A (1994) Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 21:1922–1926PubMed Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A (1994) Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 21:1922–1926PubMed
56.
go back to reference Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299PubMedCrossRef Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299PubMedCrossRef
57.
go back to reference Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013PubMedCrossRef Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15:1006–1013PubMedCrossRef
58.
go back to reference Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211PubMedCrossRef Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211PubMedCrossRef
59.
go back to reference Merck Sharpe & Dohme. Registration of Alendronate for GIOP. 2006 Merck Sharpe & Dohme. Registration of Alendronate for GIOP. 2006
60.
go back to reference Proctor & Gamble. Registration of Risedronate for GIOP. 2006 Proctor & Gamble. Registration of Risedronate for GIOP. 2006
61.
go back to reference de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, van Staa TP (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 261:170–177PubMedCrossRef de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, van Staa TP (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 261:170–177PubMedCrossRef
62.
go back to reference Pettifor JM (2000) Chronic glucocorticoid therapy and osteoporosis-an under-recognised problem in South Africa. S Afr Med J 90:1111–1112PubMed Pettifor JM (2000) Chronic glucocorticoid therapy and osteoporosis-an under-recognised problem in South Africa. S Afr Med J 90:1111–1112PubMed
63.
go back to reference McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRef McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRef
64.
go back to reference Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419PubMedCrossRef Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Brookhart MA (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419PubMedCrossRef
65.
go back to reference Naunton M, Duyvendak M, Peterson GM, Brouwers JR (2006) Practice patterns in osteoporosis prevention in patients on glucocorticoids. Osteoporos Int 17:634–635PubMedCrossRef Naunton M, Duyvendak M, Peterson GM, Brouwers JR (2006) Practice patterns in osteoporosis prevention in patients on glucocorticoids. Osteoporos Int 17:634–635PubMedCrossRef
66.
go back to reference Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162:2217–2222PubMedCrossRef Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH (2002) Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 162:2217–2222PubMedCrossRef
67.
68.
go back to reference Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMed
69.
go back to reference Naunton M (2006) Is the increase in osteoporosis prevention a result of the audit? Clin Neurol Neurosurg 108:718–719PubMedCrossRef Naunton M (2006) Is the increase in osteoporosis prevention a result of the audit? Clin Neurol Neurosurg 108:718–719PubMedCrossRef
70.
go back to reference Grol RP, Bosch MC, Hulscher ME, Eccles MP, Wensing M (2007) Planning and studying improvement in patient care: the use of theoretical perspectives. Milbank Q 85:93–138PubMedCrossRef Grol RP, Bosch MC, Hulscher ME, Eccles MP, Wensing M (2007) Planning and studying improvement in patient care: the use of theoretical perspectives. Milbank Q 85:93–138PubMedCrossRef
71.
go back to reference Wollersheim H, Burgers J, Grol R (2005) Clinical guidelines to improve patient care. Neth J Med 63:188–192PubMed Wollersheim H, Burgers J, Grol R (2005) Clinical guidelines to improve patient care. Neth J Med 63:188–192PubMed
72.
go back to reference Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ (1998) A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244:271–292PubMedCrossRef Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ (1998) A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 244:271–292PubMedCrossRef
73.
go back to reference National Osteoporosis Society (1998) Guidance on the prevention and management of corticosteroid induced osteoporosis. National Osteoporosis Society, Bath, UK National Osteoporosis Society (1998) Guidance on the prevention and management of corticosteroid induced osteoporosis. National Osteoporosis Society, Bath, UK
74.
go back to reference Royal College of Physicians (1999) Osteoporosis: Clinical guidelines for prevention and treatment. Royal College of Physicians, London, UK Royal College of Physicians (1999) Osteoporosis: Clinical guidelines for prevention and treatment. Royal College of Physicians, London, UK
75.
go back to reference Hough S (2000) Osteoporosis Clinical Guideline. South African Medical Association-Osteoporosis Working Group. S Afr Med J 90:907–944PubMed Hough S (2000) Osteoporosis Clinical Guideline. South African Medical Association-Osteoporosis Working Group. S Afr Med J 90:907–944PubMed
76.
go back to reference Dolan AL (2007) Greenwich and Bexley guidelines for identification, assessment and management of osteoporosis. Greenwich Dolan AL (2007) Greenwich and Bexley guidelines for identification, assessment and management of osteoporosis. Greenwich
77.
go back to reference Bone and Tooth Society, Royal College of Physicians, National Osteoporosis Society (2002) Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. Royal College of Physicians, London, UK Bone and Tooth Society, Royal College of Physicians, National Osteoporosis Society (2002) Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. Royal College of Physicians, London, UK
Metadata
Title
Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines
Authors
M. Duyvendak
M. Naunton
E. N. van Roon
G. A. W. Bruyn
J. R. B. J. Brouwers
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 10/2008
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0598-y

Other articles of this Issue 10/2008

Osteoporosis International 10/2008 Go to the issue